CoChat
Sign Up
PreprintCited by 4Muscle Physiology and DisordersGenomics and Rare DiseasesCardiomyopathy and Myosin Studies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Profiling of pathogenic variants in Japanese patients with sarcoglycanopathy

Open access
Shimazaki, Rui, Saito, Yoshihiko, Awaya, Tomonari, Minami, Narihiro, Kurosawa, Ryo, Hosokawa, Motoyasu, Ohara, Hiroaki, Hayashi, Shinichiro, Takeuchi, Akihide, Hagiwara, Masatoshi, Hayashi, Yukiko K, Noguchi, Satoru, Nishino, Ichizo·2024·Orphanet Journal of Rare Diseases
DOI 10.21203/rs.3.rs-4146610/v1PMC PMC11699685

Preprint — published as 10.1186/s13023-024-03521-2 · Paper page

Open this paper in CoChat — free accountOpen PDF

Abstract

Background Sarcoglycanopathies (SGPs) are limb-girdle muscular dystrophies (LGMDs) that can be classified into four types, LGMDR3, LGMDR4, LGMDR5, and LGMDR6, caused by mutations in the genes, SGCA, SGCB, SGCG, and SGCD, respectively. SGPs are relatively rare in Japan. This study aims to profile the genetic variants that cause SGPs in Japanese patients. Methods Clinical course and pathological findings were retrospectively reviewed in Japanese patients with SGP. Genetic analyses were performed using a combination of targeted resequencing with a hereditary muscle disease panel, whole genome sequencing, multiplex ligation-dependent probe amplification, and long-read sequencing. The structures of transcripts with aberrant splicing were also determined by RT-PCR, RNA-seq, and in silico prediction. Results We identified biallelic variants in SGC genes in 53 families, including three families with LGMDR6, which had not been identified in Japan so far. SGCA was the most common causative gene, accounting for 56% of cases, followed by SGCG, SGCB, and SGCD, at 17%, 21%, and 6%, respectively. Missense variants in SGCA were very frequent at 78.3%, while they were relatively rare in SGCB, SGCG, and SGCD at 11.1%, 18.2%, and 16.6%, respectively. We also analyzed the haplotypes of alleles carrying three variants found in multiple cases: c.229C > T in SGCA, c.325C > T in SGCB, and exon 6 deletion in SGCG; two distinct haplotypes were found for c.229C > T in SGCA, while each of the latter two variants was on single haplotypes. Conclusions We present genetic profiles of Japanese patients with SGPs. Haplotype analysis indicated common ancestors of frequent variants. Our findings will support genetic diagnosis and gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-4146610/v1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 STRAD flow diagram showing the genetic analysis carried out. We started with sequencing analyses, such as Sanger sequencing, panel analysis, whole-exome sequencing, or whole-genome sequencing. Aberrant splicing was detected using RNA-seq or RT-PCR in patients with exon–intron boundary or intronic variants. MLPA was applied to patients who were not diagnosed by sequencing analysis, and the breakpoints of a large SGCG deletion were identified using long-read sequencing
Fig. 1 STRAD flow diagram showing the genetic analysis carried out. We started with sequencing analyses, such as Sanger sequencing, panel analysis, whole-exome sequencing, or whole-genome sequencing. Aberrant splicing was detected using RNA-seq or RT-PCR in patients with exon–intron boundary or intronic variants. MLPA was applied to patients who were not diagnosed by sequencing analysis, and the breakpoints of a large SGCG deletion were identified using long-read sequencingCC BY · PubMed Central
Fig. 2 Locations of amino-acid changes caused by identified genetic variants in predicted protein structures. Predicted three-dimensional structures of α-sarcoglycan (Q16586 (SGCA_HUMAN)), β-sarcoglycan (Q16585 (SGCB_HUMAN)), γ-sarcoglycan (Q13326 (SGCG_HUMAN)), and δ-sarcoglycan (Q92629 (SGCD_HUMAN)), obtained from Alphafold Protein Structure Database (https://alphafold.ebi.ac.uk/). Red circles indicate the positions of missense variants. Red squares indicate in-frame deletions or insertions. Gray circles denote the positions of truncation of normal sequences in truncation variants. Yellow and white arrowheads show the 4 amino-acid deletion (13–16) caused by c.38-2A > C in SGCA and p.K32E encoded by c.94A > G in SGCD, respectively
Fig. 2 Locations of amino-acid changes caused by identified genetic variants in predicted protein structures. Predicted three-dimensional structures of α-sarcoglycan (Q16586 (SGCA_HUMAN)), β-sarcoglycan (Q16585 (SGCB_HUMAN)), γ-sarcoglycan (Q13326 (SGCG_HUMAN)), and δ-sarcoglycan (Q92629 (SGCD_HUMAN)), obtained from Alphafold Protein Structure Database (https://alphafold.ebi.ac.uk/). Red circles indicate the positions of missense variants. Red squares indicate in-frame deletions or insertions. Gray circles denote the positions of truncation of normal sequences in truncation variants. Yellow and white arrowheads show the 4 amino-acid deletion (13–16) caused by c.38-2A > C in SGCA and p.K32E encoded by c.94A > G in SGCD, respectivelyCC BY · PubMed Central
Fig. 3 Frequencies of variants and variant types in patients with sarcoglycanopathies. The frequency of (a) causative genes in Japanese patients with sarcoglycanopathies, and (b)–(e) variants in each causative gene: b SGCA, c SGCB, d SGCG, and e SGCD. Gray sections in pie charts indicate variants detected one family. f Effects of gene variants on protein products
Fig. 3 Frequencies of variants and variant types in patients with sarcoglycanopathies. The frequency of (a) causative genes in Japanese patients with sarcoglycanopathies, and (b)–(e) variants in each causative gene: b SGCA, c SGCB, d SGCG, and e SGCD. Gray sections in pie charts indicate variants detected one family. f Effects of gene variants on protein productsCC BY · PubMed Central
Fig. 4 Genome structures in patients with deletion of SGCG exon 6, SGCG exon 1 to 6 and the whole SGCG gene. a SGCG exon 6 deletion. The breakpoints were the same in all patients. b SGCG exon 1 to 6 deletion. c Whole gene deletion of SGCG; similar sequences (identity: 94%) were present in the 5' and 3' breakpoints. Repeat sequence schema were retrieved from Ensembl (https://asia.ensembl.org/index.html). SINE, short interspersed nuclear element; LINE, long interspersed nuclear element; LTR, long terminal repeat
Fig. 4 Genome structures in patients with deletion of SGCG exon 6, SGCG exon 1 to 6 and the whole SGCG gene. a SGCG exon 6 deletion. The breakpoints were the same in all patients. b SGCG exon 1 to 6 deletion. c Whole gene deletion of SGCG; similar sequences (identity: 94%) were present in the 5' and 3' breakpoints. Repeat sequence schema were retrieved from Ensembl (https://asia.ensembl.org/index.html). SINE, short interspersed nuclear element; LINE, long interspersed nuclear element; LTR, long terminal repeatCC BY · PubMed Central
Fig. 5 Splicing abnormalities and MaxEnt scores generated by analysis of intronic variants. a F1 SGCA intron 1: c.37 + 6 T > C. Sashimi plots of RNA-seq data using control and patient muscles are shown. b–e RT-PCR products obtained from control and patient muscle samples separated on agarose gels and schema showing aberrant splicing events with MaxEnt scores. White squares are normal-sized exons and gray squares are altered-sized exons. In the right schema, genetic variants are shown in red and new splicing sites are shown in light blue. * indicate the non-specific products which were not related to SGC genes. b F2 SGCA intron 1: c.38-2A > C. c F3 SGCA intron 2/exon 3: c.158-2_167del. d F25 SGCA intron 5: c.584 + 1G > A and F26 SGCA intron 5: c.584 + 5G > T. e F37 SGCB intron 5: c.753 + 5G > A. f F53 SGCD intron 6: c.502 + 24695G > T. RT-PCR and Sashimi plots of RNA-seq data are shown; sequences 5' (upstream) of the variants included a possible branch point site, a polypyrimidine tract, and a splice acceptor site. ctrl, control sample; Ref, reference sequence
Fig. 5 Splicing abnormalities and MaxEnt scores generated by analysis of intronic variants. a F1 SGCA intron 1: c.37 + 6 T > C. Sashimi plots of RNA-seq data using control and patient muscles are shown. b–e RT-PCR products obtained from control and patient muscle samples separated on agarose gels and schema showing aberrant splicing events with MaxEnt scores. White squares are normal-sized exons and gray squares are altered-sized exons. In the right schema, genetic variants are shown in red and new splicing sites are shown in light blue. * indicate the non-specific products which were not related to SGC genes. b F2 SGCA intron 1: c.38-2A > C. c F3 SGCA intron 2/exon 3: c.158-2_167del. d F25 SGCA intron 5: c.584 + 1G > A and F26 SGCA intron 5: c.584 + 5G > T. e F37 SGCB intron 5: c.753 + 5G > A. f F53 SGCD intron 6: c.502 + 24695G > T. RT-PCR and Sashimi plots of RNA-seq data are shown; sequences 5' (upstream) of the variants included a possible branch point site, a polypyrimidine tract, and a splice acceptor site. ctrl, control sample; Ref, reference sequenceCC BY · PubMed Central
Fig. 6 Haplotype analyses of alleles containing common single nucleotide polymorphism (SNP) variants. a Patients with SGCA c.229C > T. b Patients with SGCB c.325C > T. c Patients with SGCG exon 6 deletion. Bases in blue font indicate minor SNP alleles and bases in red font indicate variants. Orange shaded cells indicate homozygosity for minor SNP alleles. Yellow shaded cells indicate heterozygosity for minor SNP alleles. Blue shaded cells indicate homozygosity for major SNP alleles
Fig. 6 Haplotype analyses of alleles containing common single nucleotide polymorphism (SNP) variants. a Patients with SGCA c.229C > T. b Patients with SGCB c.325C > T. c Patients with SGCG exon 6 deletion. Bases in blue font indicate minor SNP alleles and bases in red font indicate variants. Orange shaded cells indicate homozygosity for minor SNP alleles. Yellow shaded cells indicate heterozygosity for minor SNP alleles. Blue shaded cells indicate homozygosity for major SNP allelesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 53

  1. Straub V, Murphy A, Udd B, LGMD workshop study group. 229th ENMC international workshop: Limb girdle muscular dystrophies - Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord. 2018;28:702–10.
  2. Xie Z, Hou Y, Yu M, Liu Y, Fan Y, Zhang W, et al. Clinical and genetic spectrum of sarcoglycanopathies in a large cohort of Chinese patients. Orphanet J Rare Dis. 2019;14:43. · DOI
  3. Alonso-Pérez J, González-Quereda L, Bello L, Guglieri M, Straub V, Gallano P, et al. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. 2020;143:2696–708. · DOI
  4. Dalichaouche I, Sifi Y, Roudaut C, Sifi K, Hamri A, Rouabah L, et al. γ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort. Muscle Nerve. 2017;56:129–35. · DOI
  5. Liang W-C, Chou P-C, Hung C-C, Su Y-N, Kan T-M, Chen W-Z, et al. Probable high prevalence of limb-girdle muscular dystrophy type 2D in Taiwan. J Neurol Sci. 2016;362:304–8. · DOI
  6. Alavi A, Esmaeili S, Nilipour Y, Nafissi S, Tonekaboni SH, Zamani G, et al. LGMD2E is the most common type of sarcoglycanopathies in the Iranian population. J Neurogenet. 2017;31:161–9. · DOI
  7. Mojbafan M, Bahmani R, Bagheri SD, Sharifi Z, Zeinali S. Mutational spectrum of autosomal recessive limb-girdle muscular dystrophies in a cohort of 112 Iranian patients and reporting of a possible founder effect. Orphanet J Rare Dis. 2020;15:14. · DOI
  8. Sanga S, Chakraborty S, Bardhan M, Polavarapu K, Kumar VP, Bhattacharya C, et al. Identification of a shared, common haplotype segregating with an SGCB c.544 T > G mutation in Indian patients affected with sarcoglycanopathy. Sci Rep. 2023;13:15095. · DOI
  9. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science. 1995;270:819–22. · DOI
  10. Higuchi I, Kawai H, Umaki Y, Kawajiri M, Adachi K, Fukunaga H, et al. Different manners of sarcoglycan expression in genetically proven alpha-sarcoglycan deficiency and gamma-sarcoglycan deficiency. Acta Neuropathol. 1998;96:202–6. · DOI
  11. Lee T, Tokunaga S, Taniguchi N, Misaki M, Shimomura H, Nishino I, et al. Underlying diseases in sporadic presentation of high creatine kinase levels in girls. Clin Chim Acta. 2021;519:198–203. · DOI
  12. Okubo M, Noguchi S, Awaya T, Hosokawa M, Tsukui N, Ogawa M et al. RNA-seq analysis, targeted long-read sequencing and in silico prediction to unravel pathogenic intronic events and complicated splicing abnormalities in dystrophinopathy. Hum Genet [Internet]. 2022; http://dx.doi.org/10.1007/s00439-022-02485-2 · DOI
  13. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019;176:535–e54824. · DOI · Paper page
  14. Malicdan MCV, Noguchi S, Nishino I. Chapter 19 Monitoring Autophagy in Muscle Diseases. Methods in Enzymology. Academic; 2009. pp. 379–96.
  15. Endo Y, Noguchi S, Hara Y, Hayashi YK, Motomura K, Miyatake S, et al. Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca2+ channels. Hum Mol Genet. 2015;24:637–48. · DOI
  16. Okubo M, Minami N, Goto K, Goto Y, Noguchi S, Mitsuhashi S, et al. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: validation analysis of DMD mutations. J Hum Genet. 2016;61:483–9. · DOI
  17. Shamsani J, Kazakoff SH, Armean IM, McLaren W, Parsons MT, Thompson BA, et al. A plugin for the Ensembl Variant Effect Predictor that uses MaxEntScan to predict variant spliceogenicity. Bioinformatics. 2019;35:2315–7. · DOI
  18. Kurosawa R, Iida K, Ajiro M, Awaya T, Yamada M, Kosaki K, et al. PDIVAS: Pathogenicity predictor for Deep-Intronic Variants causing Aberrant Splicing. BMC Genomics. 2023;24:601. · DOI
  19. Duncan DR, Kang PB, Rabbat JC, Briggs CE, Lidov HGW, Darras BT, et al. A novel mutation in two families with limb-girdle muscular dystrophy type 2C. Neurology. 2006;67:167–9. · DOI
  20. Tétreault M, Srour M, Allyson J, Thiffault I, Loisel L, Robitaille Y, et al. Founder mutation for α-sarcoglycan-LGMD2D in a Magdalen Islands Acadian cluster. Can J Neurol Sci. 2011;38:747–52. · DOI
  21. Reddy HM, Hamed SA, Lek M, Mitsuhashi S, Estrella E, Jones MD, et al. Homozygous nonsense mutation in SGCA is a common cause of limb-girdle muscular dystrophy in Assiut, Egypt. Muscle Nerve. 2016;54:690–5. · DOI
  22. Ferreira AFB, Carvalho MS, Resende MBD, Wakamatsu A, Reed UC, Marie SKN. Phenotypic and immunohistochemical characterization of sarcoglycanopathies. Clinics. 2011;66:1713–9.
  23. Nalini A, Gayathri N, Thaha F, Das S, Shylashree S. Sarcoglycanopathy: clinical and histochemical characteristics in 66 patients. Neurol India. 2010;58:691–6. · DOI
  24. Alonso-Pérez J, González-Quereda L, Bruno C, Panicucci C, Alavi A, Nafissi S, et al. Clinical and genetic spectrum of a large cohort of patients with δ-sarcoglycan muscular dystrophy. Brain. 2022;145:596–606. · DOI
  25. Moreira ES, Vainzof M, Suzuki OT, Pavanello RCM, Zatz M, Passos-Bueno MR. Genotype-phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations. J Med Genet. 2003;40:E12. · DOI
  26. Hackman P, Juvonen V, Sarparanta J, Penttinen M, Aärimaa T, Uusitalo M, et al. Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients. Muscle Nerve. 2005;31:199–204. · DOI
  27. Tetreault M, Srour M, Allyson J, Thiffault I. Founder mutation for a-sarcoglycan-LGMD2D in a Magdalen Islands Acadian cluster. Canadian journal of [Internet]. 2011; https://www.cambridge.org/core/journals/canadian-journal-of-neurological-sciences/article/founder-mutation-for-asarcoglycanlgmd2d-in-a-magdalen-islands-acadian-cluster/11284447A55DE04D1C0F94A0F9FC58A3
  28. Parks MM, Lawrence CE, Raphael BJ. Detecting non-allelic homologous recombination from high-throughput sequencing data. Genome Biol. 2015;16:72. · DOI
  29. Engert JC, Bérubé P, Mercier J, Doré C, Lepage P, Ge B, et al. ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet. 2000;24:120–5. · DOI · Paper page
  30. Eldomery MK, Akdemir ZC, Vögtle F-N, Charng W-L, Mulica P, Rosenfeld JA, et al. MIPEP recessive variants cause a syndrome of left ventricular non-compaction, hypotonia, and infantile death. Genome Med. 2016;8:106. · DOI
  31. Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Takeshita E, et al. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study. Ann Clin Transl Neurol. 2020;7:2393–408. · DOI
  32. Ohara H, Hosokawa M, Awaya T, Hagiwara A, Kurosawa R, Sako Y, et al. Branchpoints as potential targets of exon-skipping therapies for genetic disorders. Mol Therapy - Nucleic Acids. 2023;33:404–12. · DOI
  33. Trabelsi M, Kavian N, Daoud F, Commere V, Deburgrave N, Beugnet C, et al. Revised spectrum of mutations in sarcoglycanopathies. Eur J Hum Genet. 2008;16:793–803. · DOI
  34. Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2021;50:D439–44. · DOI · Paper page
  35. Betto R, Senter L, Ceoldo S, Tarricone E, Biral D, Salviati G. Ecto-ATPase activity of alpha-sarcoglycan (adhalin). J Biol Chem. 1999;274:7907–12. · DOI
  36. Noguchi S, Wakabayashi E, Imamura M, Yoshida M, Ozawa E. Formation of sarcoglycan complex with differentiation in cultured myocytes. Eur J Biochem. 2000;267:640–8. · DOI
  37. Chan YM, Bönnemann CG, Lidov HG, Kunkel LM. Molecular organization of sarcoglycan complex in mouse myotubes in culture. J Cell Biol. 1998;143:2033–44. · DOI
  38. Bannai H, Tamada Y, Maruyama O, Nakai K, Miyano S. Extensive feature detection of N-terminal protein sorting signals. Bioinformatics. 2002;18:298–305. · DOI
  39. Horton P, Park K-J, Obayashi T, Fujita N, Harada H, Adams-Collier CJ, et al. WoLF PSORT: protein localization predictor. Nucleic Acids Res. 2007;35:W585–7. · DOI
  40. Bardhan M, Anjanappa RM, Polavarapu K, Preethish-Kumar V, Vengalil S, Nashi S, et al. Clinical, genetic profile and disease progression of sarcoglycanopathies in a large cohort from India: high prevalence of SGCB c.544A > C. Neurogenetics. 2022;23:187–202. · DOI
  41. Piccolo F, Roberds SL, Jeanpierre M, Leturcq F, Azibi K, Beldjord C, et al. Primary adhalinopathy: a common cause of autosomal recessive muscular dystrophy of variable severity. Nat Genet. 1995;10:243–5. · DOI
  42. Tian X, Liang W-C, Feng Y, Wang J, Zhang VW, Chou C-H, et al. Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS. Neurol Genet. 2015;1:e14. · DOI
  43. Cantero D, Hernández-Laín A, Martínez JFG, Pérez MR, Ruano Y, Lleixà C, et al. Milder forms of α-sarcoglicanopathies diagnosed in adulthood by NGS analysis. J Neurol Sci. 2018;394:63–7. · DOI
  44. Higuchi I, Iwaki H, Kawai H, Endo T, Kunishige M, Fukunaga H, et al. New missense mutation in the alpha-sarcoglycan gene in a Japanese patient with severe childhood autosomal recessive muscular dystrophy with incomplete alpha-sarcoglycan deficiency. J Neurol Sci. 1997;153:100–5. · DOI
  45. Bueno MR, Moreira ES, Vainzof M, Chamberlain J, Marie SK, Pereira L, et al. A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Hum Mol Genet. 1995;4:1163–7. · DOI
  46. Dinçer P, Leturcq F, Richard I, Piccolo F, Yalnizoglu D, de Toma C, et al. A biochemical, genetic, and clinical survey of autosomal recessive limb girdle muscular dystrophies in Turkey. Ann Neurol. 1997;42:222–9. · DOI
  47. Carrié A, Piccolo F, Leturcq F, de Toma C, Azibi K, Beldjord C, et al. Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D). J Med Genet. 1997;34:470–5. · DOI
  48. Boito C, Fanin M, Siciliano G, Angelini C, Pegoraro E. Novel sarcoglycan gene mutations in a large cohort of Italian patients. J Med Genet. 2003;40:e67. · DOI
  49. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RKC, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science. 2015;347:1254806. · DOI
  50. Guglieri M, Magri F, D’Angelo MG, Prelle A, Morandi L, Rodolico C, et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat. 2008;29:258–66. · DOI
  51. Winckler PB, da Silva AMS, Coimbra-Neto AR, Carvalho E, Cavalcanti EBU, Sobreira CFR, et al. Clinicogenetic lessons from 370 patients with autosomal recessive limb-girdle muscular dystrophy. Clin Genet. 2019;96:341–53. · DOI
  52. Semplicini C, Vissing J, Dahlqvist JR, Stojkovic T, Bello L, Witting N, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 2015;84:1772–81. · DOI
  53. Takano A, Bönnemann CG, Honda H, Sakai M, Feener CA, Kunkel LM, et al. Intrafamilial phenotypic variation in limb-girdle muscular dystrophy type 2C with compound heterozygous mutations. Muscle Nerve. 2000;23:807–10. · DOI

Metadata

Authors
Shimazaki, R., Saito, Y., Awaya, T., Minami, N., Kurosawa, R., Hosokawa, M., Ohara, H., Hayashi, S., Takeuchi, A., Hagiwara, M., Hayashi, Y. K., Noguchi, S., & Nishino, I.
Affiliations
  • National Center of Neurology and Psychiatry (JP)
  • Kyoto University (JP)
  • Ehime University (JP)
  • Tokyo Medical University (JP)
Corresponding author
Noguchi, Satoru
ORCID
Venue
Orphanet Journal of Rare Diseases
Publisher
Springer Science and Business Media LLC
Published
2024-12-18
Volume
20
Issue
1
Pages
1-1
ISSN
1750-1172 (ISSN-L)
DOI
10.21203/rs.3.rs-4146610/v1
PMC
PMC11699685
OpenAlex
W4406052185
Cited by
4
References
1
Citations by year
2026: 2 · 2025: 2
FWCI
1.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Japan Agency for Medical Research and Development (JP23ak0101195s0101, JP23ek0109617s0402, JP20ek0109490h0001)
  • National Center of Neurology and Psychiatry
  • Japan Society for the Promotion of Science (22KJ2023, 23K24059, 23K16771)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Keywords
sarcoglycanopathies, limb-girdle muscular dystrophy, SGCA, SGCD, pathogenic variants, haplotype analysis, missense mutations, exon deletion, Japanese patients, genetic diagnosis, gene therapy
MeSH terms
East Asian People, Adolescent, Adult, Child, Child, Preschool, Female, Humans, Japan, Male, Middle Aged, Mutation, Retrospective Studies, Sarcoglycans, Young Adult, Sarcoglycanopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review